NRF2 is often hyperactivated in MDR cancers, leading to increased expression of antioxidants such as heme oxygenase 1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1), transporter proteins like multidrug resistance protein 1/2 (MRP1/2), and detoxifying enzymes like glutathione S-transferase (GST) [18]. The gene discussed is NFE2L2; the disease is cancer.